#USA #San Diego #IBD #cAMPfield #Prifemilast

cAMPfield Therapeutics Launches with Significant Funding to Advance IBD Treatment

cAMPfield Therapeutics has recently announced the successful completion of a $180 million Series A financing. This funding aims to support the development of prifemilast (HY1999/HPP737), an innovative oral therapy designed for the treatment of inflammatory bowel disease (IBD), which includes conditions like ulcerative colitis and Crohn's disease.

The Series A financing is led by esteemed investors like Frazier Life Sciences, along with contributions from Deep Track Capital, Forbion, Abingworth, Venrock, Longitude Capital, Novo Holdings, and RA Capital. This strong financial backing signifies a robust commitment to addressing unmet needs in the IBD treatment landscape.

The Promise of Prifemilast

Prifemilast is an oral Phosphodiesterase-4 (PDE4) inhibitor that has shown considerable efficacy in clinical trials, particularly in Phase 2 studies focusing on ulcerative colitis. This drug is characterized as potentially best-in-class among PDE4 inhibitors, which work by increasing levels of cyclic adenosine monophosphate (cAMP) within cells, thus lowering pro-inflammatory cytokines and enhancing anti-inflammatory responses. The encouraging results from previous studies support the notion that PDE4 inhibitors can play a significant role in managing IBD, yet the existing options in this category often suffer from tolerability issues.

What sets prifemilast apart is its selective inhibition of the PDE4B subtype, known for its beneficial anti-inflammatory properties, compared to the PDE4D subtype, which can lead to dose-limiting side effects. Prifemilast has been well-received in terms of tolerability, showing similar treatment discontinuation rates to placebo. This could potentially make it a preferred choice for many patients who are currently struggling with the side effects of traditional IBD medications.

Comprehensive Development Strategy

With the new funding, cAMPfield plans to initiate global Phase 2b trials for prifemilast in patients with moderate-to-severe ulcerative colitis and additional Phase 2 trials focusing on Crohn's disease. Bill Gerhart, the CEO of cAMPfield, emphasizes the pressing need for effective therapies, noting that despite the existence of several FDA-approved treatments for IBD, many patients continue to experience inadequate disease control, prompting frequent treatment switches.

Founded by Mountainfield Venture Partners, cAMPfield benefits from a leadership team composed of seasoned professionals with significant experience in developing and commercializing treatments for IBD and other immune-mediated inflammatory diseases. Notable figures in the leadership include individuals who previously contributed to the commercial success of therapies such as Humira, Entyvio, Otezla, and Zeposia, underscoring the company’s capability to navigate the complex biopharmaceutical landscape.

The Need for New Treatments

Approximately 2.4 million people in the United States suffer from IBD, presenting a substantial public health concern. The frequent inadequacies of current treatments not only emphasize the urgent need for new options but also highlight the advantage of oral therapies over injectable biologics, which are becoming increasingly prevalent yet are often seen as less convenient by patients and healthcare providers alike.

cAMPfield is dedicated to transforming the IBD treatment landscape with prifemilast, offering the potential for an improved combination of effectiveness, tolerability, and dosing convenience. The company’s approach is informed by considerable clinical experience suggesting that its investigational therapy may help establish a new standard of care for individuals living with IBD.

Conclusion

In summary, cAMPfield Therapeutics' launch marks a significant step forward in the pursuit of effective oral treatments for inflammatory bowel disease. With backed financial resources and strong leadership, the company's journey with prifemilast may represent a beacon of hope for many affected by these challenging conditions, particularly in the quest for better management options and outcomes.